Literature DB >> 26379824

Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.

Liangqing Ge1, Ruizheng Shi2.   

Abstract

To discuss the mechanism and clinical application of EGFR-TKI and ALK/ROS1 inhibitors in non-small cell lung cancer (NSCLC), we reviewed recent available data mainly from PubMed. We found that chemotherapy, progression-free survival (PFS), objective response rate (ORR), and quality of life of patients with advanced NSCLC can be greatly improved in these drugs medication compared with conventional chemotherapy. Though many questions like resistance to EGFR-TKI and ALK/ROS1 inhibitors exist, molecular targeted therapy is an important therapeutic method for the management of NSCLC. The role of molecule targeted therapy in the initiation and development of NSCLC deserves further study.

Entities:  

Keywords:  ALK/ROS1 inhibitors; EGFR-TKI inhibitors; non-small cell lung cancer

Year:  2015        PMID： 26379824      PMCID： PMC4565207     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN： 1940-5901


  65 in total

1.  Expression and rearrangement of the ROS1 gene in human glioblastoma cells.

Authors:  C Birchmeier; S Sharma; M Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

3.  Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.

Authors:  Paul K Paik; Anna M Varghese; Camelia S Sima; Andre L Moreira; Marc Ladanyi; Mark G Kris; Natasha Rekhtman
Journal:  Mol Cancer Ther       Date:  2012-08-14       Impact factor: 6.261

4.  EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.

Authors:  Xiao-Li Jia; Gang Chen
Journal:  Lung Cancer       Date:  2011-05-17       Impact factor: 5.705

5.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

6.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

7.  Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Authors:  Annette O Walter; Robert Tjin Tham Sjin; Henry J Haringsma; Kadoaki Ohashi; Jing Sun; Kwangho Lee; Aleksandr Dubrovskiy; Matthew Labenski; Zhendong Zhu; Zhigang Wang; Michael Sheets; Thia St Martin; Russell Karp; Dan van Kalken; Prasoon Chaturvedi; Deqiang Niu; Mariana Nacht; Russell C Petter; William Westlin; Kevin Lin; Sarah Jaw-Tsai; Mitch Raponi; Terry Van Dyke; Jeff Etter; Zoe Weaver; William Pao; Juswinder Singh; Andrew D Simmons; Thomas C Harding; Andrew Allen
Journal:  Cancer Discov       Date:  2013-09-24       Impact factor: 39.397

8.  Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung.

Authors:  Toshihiro Shiozawa; Genichiro Ishii; Koichi Goto; Kanji Nagai; Sachiyo Mimaki; Shotaro Ono; Seiji Niho; Satoshi Fujii; Yuichiro Ohe; Katsuya Tsuchihara; Atsushi Ochiai
Journal:  Pathol Int       Date:  2013-02-21       Impact factor: 2.534

9.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

10.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582
View more
  12 in total

1.  Mutational landscape and clonal diversity of pulmonary adenoid cystic carcinoma.

Authors:  Min Li; Bing-Rong Zhao; Shi-Qing Liu; Jian An; Peng-Bo Deng; Han Han-Zhang; Jun-Yi Ye; Xin-Ru Mao; Shao-Kun Chuai; Cheng-Ping Hu
Journal:  Cancer Biol Ther       Date:  2018-08-01       Impact factor: 4.742

2.  Knockdown of Immature Colon Carcinoma Transcript 1 Inhibits Proliferation and Promotes Apoptosis of Non-Small Cell Lung Cancer Cells.

Authors:  Yiling Wang; Jiantao He; Shenghui Zhang; Qingbo Yang; Bo Wang; Zhiyu Liu; Xintian Wu
Journal:  Technol Cancer Res Treat       Date:  2016-07-13

3.  L-securinine inhibits the proliferation of A549 lung cancer cells and promotes DKK1 promoter methylation.

Authors:  Shuwen Han; Xi Yang; Yuefen Pan; Quan Qi; Junjun Shen; Huifen Fang; Zhaoning Ji
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

4.  Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.

Authors:  Minghui Zhang; Hongsheng Guo; Shu Zhao; Yan Wang; Maopeng Yang; Jiawei Yu; Yubo Yan; Yan Wang
Journal:  Oncotarget       Date:  2016-06-28

5.  The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients.

Authors:  Liming Cao; Long Long; Min Li; Huaping Yang; Pengbo Deng; Xinru Mao; Jianxing Xiang; Bing Li; Tengfei Zhang; Chengping Hu
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

6.  Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer.

Authors:  Ying Jin; Ming Chen; Xinmin Yu
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379

Review 7.  Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

Authors:  Lei-Yun Wang; Jia-Jia Cui; Ao-Xiang Guo; Ji-Ye Yin
Journal:  Onco Targets Ther       Date:  2018-01-24       Impact factor: 4.147

8.  Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.

Authors:  Junjie Piao; Liyan Chen; Taihao Quan; Longshan Li; Chunji Quan; Yingshi Piao; Tiefeng Jin; Zhenhua Lin
Journal:  Oncotarget       Date:  2016-09-13

9.  Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.

Authors:  Ying Jin; Yang Shao; Xun Shi; Guangyuan Lou; Yiping Zhang; Xue Wu; Xiaoling Tong; Xinmin Yu
Journal:  Oncotarget       Date:  2016-09-20

10.  Evodiamine, a Novel NOTCH3 Methylation Stimulator, Significantly Suppresses Lung Carcinogenesis in Vitro and in Vivo.

Authors:  Tao Su; Xia Yang; Jian-Hua Deng; Qiu-Ju Huang; Su-Chao Huang; Yan-Min Zhang; Hong-Ming Zheng; Ying Wang; Lin-Lin Lu; Zhong-Qiu Liu
Journal:  Front Pharmacol       Date:  2018-05-01       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.